
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
Audio By Carbonatix COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up …